Bionano Genomics Announces Extensive Lineup of Content at Association for Molecular Pathology (AMP) Annual Meeting Featuring OGM Utility Across Broad Range of Research Applications
October 28 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its
participation in the Association for Molecular Pathology (AMP)
Annual Meeting and Expo 2022 with a broad range of content covering
optical genome mapping’s (OGM) utility for research applications
including prenatal and postnatal analysis, genetic disease and
hematological malignancies.
AMP’s Annual Meeting brings together industry, medical, and
academic professionals to discuss advances in the field of
molecular diagnostics. The AMP conference will be held November
1-5, 2022, in Phoenix, Arizona.
Scientific presentations and poster sessions from Bionano and
collaborators include:
Session |
Title |
Presenter |
Presented |
Corporate Workshop |
Maximizing Detection of Pathogenic Structural Variants Across
Hematological Malignancies with Optical Genome Mapping |
Chaubey A., Sahajpal N., Kanagal-Shamanna R., Smith A. |
November 2, 20229:00-9:50 AM PDTRoom 229 AB |
Corporate Workshop |
Comprehensive Assessment of HRD From Next-Generation Sequencing and
Optical Genome Mapping |
Chaubey A., Kanagal-Shamanna R., Kolhe R., Lum C. |
November 2, 202210:00-10:50 AM PDTRoom 229 AB |
Plenary Session |
Implementation of Long-Read Sequencing and Optical Genome Mapping
in the Cytogenetic Laboratory |
Smith A. |
November 4, 20223:45-5:15 PM PDTSee program for location |
Plenary Session |
Next Generation Cytogenomics |
Smith A., Duncavage E., Akkari Y., Hasserjian R. |
November 4, 20223:45-5:15 PM PDTSee program for location |
Poster Title |
Author/ Affiliation |
Even-Numbered Posters: Friday, November 4 | 9:15 AM – 10:15
AMOdd-Numbered Posters: Saturday, November 5 |
9:15 AM – 10:15 AM |
|
Are we using the right tools to calculate homologous recombination
deficiency (HRD) scores? |
Kolhe LabAugusta University |
Compound heterozygous events in myeloid tumors: Next-generation
approach with optical genome mapping and a 523-gene NGS panel |
Kolhe LabAugusta University |
Mosaic structural variation detection with optical genome mapping:
Lower limit of detection study |
Kolhe LabAugusta University |
Bringing a new technology in CLIA laboratory: Our experience of
clinical validation, getting AMA PLA code, and the Moldx Z-code for
optical genome mapping for evaluation of hematological
neoplasms |
Kolhe LabAugusta University |
Going beyond karyotyping and FISH: Impact of optical genome mapping
(OGM) with additional clinically relevant information in 75
hematological malignancy cases |
Kolhe LabAugusta University |
Optical genome mapping: a potential tier I test for prenatal
diagnostic testing |
Kolhe LabAugusta University |
Clinical validation of optical genome mapping for postnatal
application |
Kolhe LabAugusta University |
Retrospective optical genome mapping analysis of FSHD1 and 2
negative patients with diminished methylation revealed exon
deletions of SMCHD1 |
Stence LabUniversity of Iowa |
NGS copy number signatures in the assessment of cancers of unknown
origin: Targeting therapy |
Lum LabQueens Medical Center |
Higher resolution and accurate breakpoint determination of a
balanced translocation by optical genome mapping |
Serrano M.Bionano Laboratories |
Optical genome mapping workflow for somatic abnormality detection
in multiple solid tumor types |
Yu J.Bionano Genomics |
“We are excited to see the highest number yet of presentations
featuring OGM at AMP this year, demonstrating OGM’s utility for
cutting-edge research applications in molecular pathology. We are
also pleased to see sessions and posters covering the combination
of OGM with NGS data to provide a more comprehensive picture of the
genome,” commented Erik Holmlin, president and chief executive
officer of Bionano.
More details on the conference can be found here.
About Bionano Genomics
Bionano Genomics is a provider of genome
analysis solutions that can enable researchers and clinicians to
reveal answers to challenging questions in biology and medicine.
The Company’s mission is to transform the way the world sees the
genome through OGM solutions, diagnostic services and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. Through its Lineagen,
Inc. d/b/a Bionano Laboratories business, the
Company also provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information,
visit www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the ability and
utility of OGM to complement next generation sequencing (NGS) and
provide a more comprehensive analysis of the genome for
applications in genetic disease and cancer research. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the impact of the COVID-19 pandemic on our
business and the global economy; general market conditions; changes
in the competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; failure of
OGM to achieve useful complementarity with NGS; failure of OGM to
be adopted for research applications; the ability of our OGM
solutions to offer the anticipated benefits for and contributions
to the areas of research reported in the presentations given and
posters made available at the AMP Annual Meeting and Expo 2022;
future study results contradicting the results reported in the
presentations given and posters made available at the AMP Annual
Meeting and Expo 2022; changes in our strategic and commercial
plans; our ability to obtain sufficient financing to fund our
strategic plans and commercialization efforts; the ability of
medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2021 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024